Smarter Imaging of Breast Cancer

Overview

The Smarter Imaging of Breast Cancer is directed at finding better ways, using imaging techniques, to detect breast cancer earlier and more accurately, to characterize it, guide the selection of therapy, deliver chemotherapy more effectively, and monitor response to therapy.

We are doing this by developing new approaches that (1) use bi-specific radionuclide probes to characterize the heterodimerization status of the HER2 receptors HER2 and HER3 to predict responsiveness to and optimize the selection of trastuzumab and/or pertuzumab therapies for breast cancer, (2) manage and characterize of Ductal Carcinoma in-Situ (DCIS) by ultrasound microbubble technique, (3) develop quantitative ultrasound and optical methods for determining response to treatment in Locally Advanced Breast Cancer (LABC), (4) improve the efficiency of chemotherapy treatment and pain palliation in breast cancer bone metastasis using MRI guided focused ultrasound, and (5) improve clinically validated CAD technique for MRI breast cancer screening for high risk women.

Sub-Projects

  • Formulation of a Kit Under GMP Conditions to Prepare 111In-Pertuzumab to Support a Phase I/II Clinical Trial to Predict Response to Trastuzumab (Herceptin) in HER2 Positive Metastatic Breast Cancer. PI: Raymond Reilly, University of Toronto;
  • Clinical Trial: Microbubble Contrast Ultrasound and Transient Elastography Imaging of Early breast cancer. PI: Martin Yaffe, Sunnybrook Research Institute. This component is integrated with the OICR Improved Management of Early Cancer (IMEC) Translational Research Initiative;
  • Combined Ultrasound and Optical Methods for Locally Advanced Breast Cancer Care. PI: Greg Czarnota, Sunnybrook Research Institute;
  • MRI-guided and Controlled Local Chemotherapy in breast cancer patients. PI: Kullervo Hynynen, Sunnybrook Research Institute;
  • Computer Aided Diagnosis for MRI Screening of the Breast in High Risk Women. PI: Anne Martel, Sunnybrook Research Institute.

Lead Principal Investigators

Dr. Martin Yaffe, Sunnybrook Research Institute
Dr. Gregory Czarnota, Sunnybrook Research Institute